| WB | 咨询技术 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 1/50-1/200 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 1/2000-1/5000 | Human,Mouse,Rat |
| Aliases | NNE; PPH; MPB1; ENO1L1 |
| WB Predicted band size | 47 kDa |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human, Mouse, Rat |
| Immunogen | Fusion protein of human ENO1 |
| Formulation | Purified antibody in PBS with 0.05% sodium azide and 50% glycerol. |
+ +
以下是关于ENO1抗体的3篇代表性文献，按研究领域分类简要概括：
---
### 1. **标题**：*Autoantibodies to alpha-enolase in patients with lung cancer*
**作者**：Pratesi F. et al.
**摘要**：研究检测了肺癌患者血清中ENO1自身抗体的水平，发现其显著高于健康对照组，提示ENO1抗体可能作为肺癌早期诊断的生物标志物。
---
### 2. **标题**：*Alpha-enolase: a target of antibodies in infectious and autoimmune diseases*
**作者**：Terrier B. et al.
**摘要**：综述了ENO1在感染和自身免疫疾病(如类风湿关节炎、系统性红斑狼疮)中的双重作用，指出抗ENO1抗体可能通过分子模拟机制导致组织损伤。
---
### 3. **标题**：*Anti-ENO1 autoantibodies as a potential biomarker for predicting postoperative sepsis outcomes*
**作者**：Huang Z. et al.
**摘要**：通过队列研究发现，脓毒症患者血清中抗ENO1抗体水平升高与预后不良相关，提示其可作为重症感染患者的预后评估指标。
---
### 领域覆盖：
- **癌症诊断**(Pratesi研究)、
- **自身免疫机制**(Terrier综述)、
- **感染预后**(Huang研究)。
如需扩展其他方向(如ENO1抗体靶向治疗)，可补充文献信息。
The ENO1 antibody targets alpha-enolase (ENO1), a glycolytic enzyme encoded by the *ENO1* gene. ENO1 catalyzes the conversion of 2-phosphoglycerate to phosphoenolpyruvate in glycolysis but also exhibits non-glycolytic functions, including roles in hypoxia response, RNA binding, and extracellular matrix interactions. Dysregulation of ENO1 is linked to cancer progression, autoimmune disorders, and inflammatory diseases. In cancers such as lung, breast, and pancreatic adenocarcinoma, ENO1 is often overexpressed, promoting tumor growth, metastasis, and immune evasion. Antibodies against ENO1 are thus valuable tools for studying its oncogenic mechanisms and potential as a therapeutic target or biomarker.
In autoimmune contexts, anti-ENO1 autoantibodies are implicated in diseases like rheumatoid arthritis and systemic lupus erythematosus, where they contribute to tissue damage by cross-reacting with human antigens. ENO1 antibodies are also utilized in research to investigate its dual localization (cytosolic, cell-surface, or secreted forms) and interactions with plasminogen or extracellular proteins. Commercially available ENO1 antibodies (polyclonal/monoclonal) are widely used in techniques like Western blotting, immunohistochemistry, and ELISA. However, specificity challenges may arise due to ENO1's homology with other enolase isoforms (e.g., ENO2/ENO3). Ongoing studies aim to refine antibody validation and explore therapeutic applications, including antibody-drug conjugates or immune checkpoint modulation.
×
